Hydroxychloroquine \[Plaquenil\] is associated with a risk of QT interval prolongation and drug interactions when used in the management of COVID-19, warns the Malaysian National Pharmaceutical Regulatory Agency (NPRA).

Hydroxychloroquine alone or in combination with other drugs is not approved for the treatment of COVID-19, but has been used off-label for this infection. It has been documented to cause dose-dependent QT interval prolongation, and is associated with a risk of cardiac adverse events (AEs) which is increased when the drug is used in patients receiving other drugs which prolong the QT interval (antiarrhythmics, tricyclic antidepressants, antipsychotics and anti-infectives including azithromycin), and in patients with pre-existing conditions which potentiate the risk of QT interval prolongation (heart disease, heart failure, myocardial infarction, bradycardia, hypocalcaemia, hypokalaemia and/or hypomagnesaemia, or a history of ventricular arrhythmias). Serious and life-threatening AEs reported after the use of hydroxychloroquine in patients with COVID-19 include QT interval prolongation, torsades de pointes, syncope, heart arrest and sudden death.

Hydroxychloroquine is also associated with known drug interactions with antacids; CYP2C8 and CYP3A4 inhibitors including cimetidine, clarithromycin, clopidogrel, gemfibrozil, itraconazole, ritonavir and grapefruit juice; and CYP2C8 and CYP3A4 inducers including carbamazepine, hypericum (St John\'s Wort), phenobarbital and rifampicin. It has an inhibitory effect on P-glycoprotein substrates including ciclosporin, dabigatran and digoxin.

The NPRA has approved a Direct Healthcare Professional Communication issued by Sanofi-aventis (Malaysia) regarding this safety concern.
